Evidence map›Paper›PMID 40500503›Full record

ReviewAdvances in neurobiology2025

Oligodendrocyte and Myelin Pathophysiology in Multiple Sclerosis.

Eneritz López-Muguruza, Carla Peiró-Moreno, Asier Ruiz, Carlos Matute

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eneritz López-Muguruza *Department of Neurosciences, University of the Basque Country UPV/EHU, IIS-BioBizkaia and CIBERNED, Leioa, Spain.
Carla Peiró-Moreno *Department of Neurosciences, University of the Basque Country UPV/EHU, IIS-BioBizkaia and CIBERNED, Leioa, Spain.
Asier RuizDepartment of Neurosciences, University of the Basque Country UPV/EHU, IIS-BioBizkaia and CIBERNED, Leioa, Spain. asier.ruiz@ehu.eus.
Carlos MatuteDepartment of Neurosciences, University of the Basque Country UPV/EHU, IIS-BioBizkaia and CIBERNED, Leioa, Spain. carlos.matute@ehu.eus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic autoimmune and progressive neurodegenerative disease of the central nervous system (CNS) that has a highly variable clinical manifestation and course. MS targets primarily myelin and oligodendroglia; however, all glial cells and neurons become involved early in the pathology. Thus, inflammation, which is widely thought to be initiated peripherally, expands through the CNS, with astrocytes and microglia entering an activated state not only around and within lesions but also widespread. This chapter will emphasize the pathophysiological changes in oligodendrocytes and myelin as a consequence of the inflammatory cascade driving the disease onset and progression. Learning about the mechanisms of oligodendrocyte and myelin damage beyond the immune attack will be instrumental in protecting these two CNS compartments from damage. In turn, knowledge about the axon-myelin unit will help in devising therapies to prevent axonal degeneration, a key clinical hallmark of MS, as it strongly correlates with the progression of CNS atrophy and symptoms. Finally, exploiting paradigms of oligodendrocyte repopulation and remyelination will definitively contribute to devising treatments for tissue repair and halting MS course. This chapter aims at summarizing the state of the art in all these experimental developments including the available clinical therapies and the current clinical trials.

Indexed as

Multiple SclerosisMyelin SheathOligodendrogliaAnimalsHumansRemyelinationAutoimmune diseaseMultiple sclerosisNeurodegenerationOligodendroglia

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.